Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
July 30 2020 - 4:01PM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that Ted Schroeder, Chief Executive Offer at Nabriva,
will provide a company overview and business update at the 2020
Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August
12th, at 2:20p.m. ET.
The presentation will be webcast live and may be
accessed by visiting the "Investors" section of the Company's
website under the "Events and Presentations" tab at
www.nabriva.com. A replay of the webcast will be available for 90
days.
About Nabriva
Therapeutics
Nabriva Therapeutics is a biopharmaceutical company
engaged in the commercialization and development of innovative
anti-infective agents to treat serious infections. Nabriva
Therapeutics received U.S. Food and Drug Administration approval
for XENLETA® (lefamulin injection, lefamulin tablets), the first
systemic pleuromutilin antibiotic for community-acquired bacterial
pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™
(fosfomycin) for injection, a potential first-in-class epoxide
antibiotic for complicated urinary tract infections (cUTI),
including acute pyelonephritis.
Forward-Looking Statements
Any statements in this press release about future
expectations, plans and prospects for Nabriva Therapeutics,
including but not limited to statements about Nabriva Therapeutics’
ability to successfully launch and commercialize XENLETA for the
treatment of CABP or CAP, including the availability of and ease of
access to XENLETA in Europe and through major U.S. specialty
distributors, marketing exclusivity and patent protection for
XENLETA, the development of CONTEPO for cUTI, the clinical utility
of XENLETA for CABP and of CONTEPO for cUTI, plans for and timing
of the review of regulatory filings for CONTEPO, efforts to bring
CONTEPO to market, the market opportunity for and the potential
market acceptance of XENLETA for CABP or CAP and CONTEPO for cUTI,
the development of XENLETA and CONTEPO for additional indications,
the development of additional formulations of XENLETA and CONTEPO,
plans to pursue research and development of other product
candidates, the sufficiency of Nabriva Therapeutics’ existing cash
resources and its expectations regarding anticipated revenues from
product sales and how far into the future its existing cash
resources will fund its ongoing operations and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “likely,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: Nabriva Therapeutics’ ability to
successfully implement its commercialization plans for XENLETA and
whether market demand for XENLETA is consistent with its
expectations, Nabriva Therapeutics’ ability to build and maintain a
sales force for XENLETA, the content and timing of decisions made
by the European Commission, the U.S. Food and Drug Administration
and other regulatory authorities, the uncertainties inherent in the
initiation and conduct of clinical trials, availability and timing
of data from clinical trials, whether results of early clinical
trials or studies in different disease indications will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of CONTEPO for the treatment of cUTI, the
ability to retain and hire key personnel, the availability of
adequate additional financing on acceptable terms or at all and
such other important factors as are set forth in Nabriva
Therapeutics’ annual and quarterly reports and other filings on
file with the U.S. Securities and Exchange Commission. In addition,
the forward-looking statements included in this press release
represent Nabriva Therapeutics’ views as of the date of this press
release. Nabriva Therapeutics anticipates that subsequent events
and developments will cause its views to change. However, while
Nabriva Therapeutics may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Nabriva Therapeutics’ views as
of any date subsequent to the date of this press release.
CONTACTS:
For InvestorsGary SenderNabriva
Therapeutics plcir@nabriva.com
For MediaMike BeyerSam Brown
Inc.mikebeyer@sambrown.com312-961-2502
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024